Moving immune checkpoint blockade in thoracic tumors beyond NSCLC

Journal of Thoracic Oncology

Volumn 11, Issue 11, 2016, Pages 1819-1836

  Facchinetti, Francesco ^a,b   Marabelle, Aurélien ^c   Rossi, Giulio ^d   Soria, Jean Charles ^a,c,e   Besse, Benjamin ^c,e   Tiseo, Marcello ^b  

^a INSERM   (France)

^b UNIVERSITY HOSPITAL OF PARMA   (Italy)

^c INSTITUT GUSTAVE ROUSSY   (France)

^d UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^e UNIVERSITÉ PARIS SACLAY   (France)

Author keywords

Immune checkpoint inhibitors; Malignant pleural mesothelioma; SCLC; Thymic epithelial tumors

Indexed keywords

CHECKPOINT KINASE INHIBITOR; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; PROGRAMMED DEATH 1 LIGAND 1;

ADVANCED CANCER; CANCER IMMUNOTHERAPY; CYTOTOXIC T LYMPHOCYTE; DRUG TARGETING; HUMAN; IMMUNOPHARMACOLOGY; MULTIMODALITY CANCER THERAPY; NON SMALL CELL LUNG CANCER; PHARMACOLOGICAL BLOCKING; PHASE 2 CLINICAL TRIAL (TOPIC); PLEURA MESOTHELIOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SMALL CELL LUNG CANCER; THORAX TUMOR; THYMIC EPITHELIAL TUMOR; THYMOMA; CELL CYCLE CHECKPOINT; DRUG EFFECTS; IMMUNOLOGY; IMMUNOTHERAPY; LUNG TUMOR; MESOTHELIOMA; PATHOLOGY; PLEURA TUMOR; PROCEDURES;

CARCINOMA, NON-SMALL-CELL LUNG; CELL CYCLE CHECKPOINTS; HUMANS; IMMUNOTHERAPY; LUNG NEOPLASMS; MESOTHELIOMA; PLEURAL NEOPLASMS; THORACIC NEOPLASMS;

EID: 84995973172     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1016/j.jtho.2016.05.027     Document Type: Review

References (138)

1. Dunn GP, Old LJ, Schreiber RD. The immunobiology of cancer immunosurveillance and immunoediting. Immunity. 2004;21:137-148.
2. Chen DS, Mellman I. Oncology meets immunology: the cancer-immunity cycle. Immunity. 2013;39:1-10.
3. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12: 252-264.
4. Mellman I, Coukos G, Dranoff G. Cancer immunotherapy comes of age. Nature. 2011;480:480-489.
5. Dieu-Nosjean M-C, Antoine M, Danel C, et al. Long-term survival for patients with non-small-cell lung cancer with intratumoral lymphoid structures. J Clin Oncol. 2008;26:4410-4417.
6. Germain C, Gnjatic S, Tamzalit F, et al. Presence of B cells in tertiary lymphoid structures is associated with a protective immunity in patients with lung cancer. Am J Respir Crit Care Med. 2014;189:832-844.
7. Melero I, Hervas-Stubbs S, Glennie M, et al. Immunos-timulatory monoclonal antibodies for cancer therapy. Nat Rev Cancer. 2007;7:95-106.
8. Rudd CE, Taylor A, Schneider H. CD28 and CTLA-4 coreceptor expression and signal transduction. Immunol Rev. 2009;229:12-26.
9. Pardoll D. Does the immune system see tumors as foreign or self? Annu Rev Immunol. 2003;21:807-839.
10. Beatty GL, Gladney WL. Immune escape mechanisms as a guide for cancer immunotherapy. Clin Cancer Res. 2015;21:687-692.
11. Kerkar SP, Restifo NP. Cellular constituents of immune escape within the tumor microenvironment. Cancer Res. 2012;72:3125-3130.
12. Herbst RS, Soria JC, Kowanetz M, et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature. 2014;515: 563-567.
13. Taube JM, Klein A, Brahmer JR, et al. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin Cancer Res. 2014;20:5064-5074.
14. Ilie M, Long-Mira E, Bence C, et al. Comparative study of the PD-L1 status between surgically resected specimens and matched biopsies of NSCLC patients reveal major discordances: a potential issue for anti-PD-L1 therapeutic strategies. Ann Oncol. 2016;27:147-153.
15. McLaughlin J, Han G, Schalper KA, et al. Quantitative assessment of the heterogeneity of PD-L1 expression in non-small-cell lung cancer. JAMA Oncol. 2016;2:46-54.
16. Madore J, Vilain RE, Menzies AM, et al. PD-L1 expression in melanoma shows marked heterogeneity within and between patients: implications for anti-PD-1/PD-L1 clinical trials. Pigment Cell Melanoma Res. 2015;28: 245-253.
17. Kakavand H, Wilmott JS, Menzies AM, et al. PD-L1 expression and tumor-infiltrating lymphocytes define different subsets of MAPK inhibitor-treated melanoma patients. Clin Cancer Res. 2015;21:3140-3148.
18. Sheng J, Fang W, Yu J, et al. Expression of programmed death ligand-1 on tumor cells varies pre and post chemotherapy in non-small cell lung cancer. Sci Rep. 2016;6:20090.
19. Simpson TR, Li F, Montalvo-Ortiz W, et al. Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma. J Exp Med. 2013;210:1695-1710.
20. Schadendorf D, Hodi FS, Robert C, et al. Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma. J Clin Oncol. 2015;33:1889-1894.
21. Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366:2443-2454.
22. Hamid O, Robert C, Daud A, et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med. 2013;369:134-144.
23. Garon EB, Rizvi NA, Hui R, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med. 2015;372:2018-2028.
24. Brahmer JR, Tykodi SS, Chow LQ, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012;366:2455-2465.
25. Boyerinas B, Jochems C, Fantini M, et al. Antibody-dependent cellular cytotoxicity activity of a novel anti-PD-L1 antibody avelumab (MSB0010718C) on human tumor cells. Cancer Immunol Res. 2015;3:1148-1157.
26. Wolchok JD, Kluger H, Callahan MK, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med. 2013;369:122-133.
27. Smyth MJ, Ngiow SF, Ribas A, et al. Combination cancer immunotherapies tailored to the tumour microenviron-ment. Nat Rev Clin Oncol. 2016;13:143-158.
28. Eggermont AM, Chiarion-Sileni V, Grob JJ, et al. Adjuvant ipilimumab versus placebo after complete resec-tion of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial. Lancet Oncol. 2015;16:522-530.
29. Twyman-Saint Victor C, Rech AJ, Maity A, et al. Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature. 2015;520:373-377.
30. American Cancer Society. Cancer Facts & Figures 2014. Atlanta, GA: American Cancer Society; 2014.
31. Byers LA, Rudin CM. Small cell lung cancer: where do we go from here? Cancer. 2015;121:664-672.
32. Oze I, Hotta K, Kiura K, et al. Twenty-seven years of phase III trials for patients with extensive disease small-cell lung cancer: disappointing results. PLoS One. 2009;4:e7835.
33. Pietanza MC, Byers LA, Minna JD, Rudin CM. Small cell lung cancer: will recent progress lead to improved outcomes? Clin Cancer Res. 2015;21:2244-2255.
34. Rudin CM, Pietanza MC, Spigel DR, et al. A DLL3-targeted adc, rovalpituzumab tesirine, demonstrates substantial activity in a phase I study in relapsed and refractory SCLC. J Thorac Oncol. 2015;10(suppl 2): S192 S193.
35. Spigel DR, Socinski MA. Rationale for chemotherapy, immunotherapy, and checkpoint blockade in SCLC: beyond traditional treatment approaches. J Thorac Oncol. 2013;8:587 598.
36. Granot Z, Fridlender ZG. Plasticity beyond cancer cells and the "immunosuppressive switch" Cancer Res. 2015;75:4441-4445.
37. Galdiero MR, Bonavita E, Barajon I, et al. Tumor associated macrophages and neutrophils in cancer. Immunobiology. 2013;218:1402-1410.
38. Tran Janco JM, Lamichhane P, Karyampudi L, et al. Tumor-infiltrating dendritic cells in cancer pathogenesis. J Immunol. 2015;194:2985 2991.
39. Meirow Y, Kanterman J, Baniyash M. Paving the road to tumor development and spreading: myeloid-derived suppressor cells are ruling the fate. Front Immunol. 2015;6:523.
40. Ding T, Yan F, Cao S, et al. Regulatory B cell: new member of immunosuppressive cell club. Hum Immunol. 2015;76:615 621.
41. Roychoudhuri R, Eil RL, Restifo NP. The interplay of effector and regulatory T cells in cancer. Curr Opin Immunol. 2015;33:101-111.
42. Harimoto H, Shimizu M, Nakagawa Y, et al. Inactivation of tumor-specific CD8∗CTLs by tumor-infiltrating tolerogenic dendritic cells. Immunol Cell Biol. 2013;91:545-555.
43. Hasmim M, Messai Y, Ziani L, et al. Critical role of tumor microenvironment in shaping NK cell functions: implication of hypoxic stress. Front Immunol. 2015;6:482.
44. Voron T, Marcheteau E, Pernot S, et al. Control of the immune response by pro- A ngiogenic factors. Front Oncol. 2014;4:70.
45. Huang Y, Yuan J, Righi E, et al. Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy. Proc Natl Acad Sci USA. 2012;109:17561 17566.
46. Huang Y, Goel S, Duda DG, et al. Vascular normalization as an emerging strategy to enhance cancer immunotherapy. Cancer Res. 2013;73:2943 2948.
47. Eerola AK, Soini Y, Pääkkö P. A high number of tumor-infiltrating lymphocytes are associated with a small tumor size, low tumor stage, and a favorable prognosis in operated small cell lung carcinoma. Clin Cancer Res. 2000;6:1875 1881.
48. Wang W, Hodkinson P, McLaren F, et al. Histologic assessment of tumor- A ssociated CD45(+) cell numbers is an independent predictor of prognosis in small cell lung cancer. Chest. 2013;143:146-151.
49. Wang W, Hodkinson P, McLaren F. Small cell lung cancer tumour cells induce regulatory T lymphocytes, and patient survival correlates negatively with FOXP3+ cells in tumour infiltrate. Int J Cancer. 2012;131:E928-E937.
50. Koyama K, Kagamu H, Miura S, et al. Reciprocal CD4+ T-cell balance of effector CD62Llow CD4+ and CD62LhighCD25+ CD4+ regulatory T cells in small cell lung cancer reflects disease stage. Clin Cancer Res. 2008;14:6770-6779.
51. Studnicka M, Wirnsberger R, Neumann M, et al. Peripheral blood lymphocyte subsets and survival in small-cell lung cancer. Chest. 1994;105:1673-1678.
52. Al Omar SY, Marshall E, Middleton D, et al. Increased numbers but functional defects of CD56+CD3+ cells in lung cancer. Int Immunol. 2012;24:409-415.
53. Karagöz B, Bilgi O, Gümüs M, et al. CD8+CD28-cells and CD4+CD25+ regulatory Tcells in the peripheral blood of advanced stage lung cancer patients. Med Oncol. 2010;27:29-33.
54. Snyder A, Makarov V, Merghoub T, et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med. 2014;371:2189-2199.
55. Van Allen EM, Miao D, Schilling B, et al. Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. Science. 2015;350:207-211.
56. Le DT, Uram JN, Wang H, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med. 2015;372:2509-2520.
57. Rizvi NA, Hellmann MD, Snyder A, et al. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science. 2015;348:124-128.
58. Schumacher TN, Schreiber RD. Neoantigens in cancer immunotherapy. Science. 2015;348:69-74.
59. Alexandrov LB, Nik-Zainal S, Wedge DC, et al. Signatures of mutational processes in human cancer. Nature. 2013;500:415-421.
60. Vogelstein B, Papadopoulos N, Velculescu VE, et al. Cancer genome landscapes. Science. 2013;339: 1546-1558.
61. Dalmau J, Rosenfeld MR. Paraneoplastic syndromes of the CNS. Lancet Neurol. 2008;7:327-340.
62. Pelosof LC, Gerber DE. Paraneoplastic syndromes: an approach to diagnosis and treatment. Mayo Clin Proc. 2010;85:838-854.
63. Graus F, Dalmou J, Reñé R, et al. Anti-Hu antibodies in patients with small-cell lung cancer: association with complete response to therapy and improved survival. J Clin Oncol. 1997;15:2866-2872.
64. Poepel A, Jarius S, Heukamp LC, et al. Neurological course of long-term surviving patients with SCLC and anti-Hu syndrome. J Neurol Sci. 2007;263:145-148.
65. Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous non small-cell lung cancer. N Engl J Med. 2015;373:1627-1639.
66. Kerr KM, Tsao MS, Nicholson AG, et al. Programmed death-ligand 1 immunohistochemistry in lung cancer: in what state is this art? J Thorac Oncol. 2015;10: 985-989.
67. Ishii H, Azuma K, Kawahara A, et al. Significance of programmed cell death-ligand 1 expression and its as-sociation with survival in patients with small cell lung cancer. J Thorac Oncol. 2015;10:426-430.
68. Komiya T, Madan R. PD-L1 expression in small cell lung cancer. Eur J Cancer. 2015;51:1853 1855.
69. Schultheis AM, Scheel AH, Ozretic L, et al. PD-L1 expression in small cell neuroendocrine carcinomas. Eur J Cancer. 2015;51:421-426.
70. Yu H, Badzio A, Boyle TA, et al. Association of expression of PD-L1 with the tumor immune microenvironment in small cell lung cancer. J Thorac Oncol. 2015;10 (suppl 2):S222 S223.
71. Yamane H, Isozaki H, Takeyama M, et al. Programmed cell death protein 1 and programmed death-ligand 1 are expressed on the surface of some small-cell lung cancer lines. Am J Cancer Res. 2015;5: 1553-1557.
72. Remon J, Chaput N, Planchard D. Predictive biomarkers for programmed death-1/programmed death ligand immune checkpoint inhibitors in non small cell lung cancer. Curr Opin Oncol. 2016;28:122 129.
73. Reck M, Bondarenko I, Luft A, et al. Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial. Ann Oncol. 2013;24:75-83.
74. Ottensmeier CHH, Galea I, Cross N, et al. A novel phase II trial of ipilimumab, carboplatin and etoposide (ICE) for the first line treatment of extensive stage small cell lung cancer (SCLC). Ann Oncol. 2014;25 (suppl 4):iv511-iv516.
75. Ott PA, Elez E, Hiret S, et al. Pembrolizumab for ED SCLC: efficacy and relationship with PD-L1 expression. J Thorac Oncol. 2015;10(suppl 2):S193.
76. Calvo E, López-Martin JA, Bendell J, et al. Nivolumab monotherapy or in combination with ipilimumab for treatment of recurrent small cell lung cancer (SCLC). Eur J Cancer. 2015;5(suppl 3):S633.
77. Antonia SJ, Bendell J, Taylor M, et al. Phase I/II study of nivolumab with or without ipilimumab for treatment of recurrent small cell lung cancer (SCLC): CA209-032. J Clin Oncol. 2015;33(suppl):7503.
78. Wolchok JD, Hoos A, O'Day S, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res. 2009;15:7412-7420.
79. Lynch TJ, Bondarenko I, Luft A, et al. Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-celllung cancer: results from a randomized, double-blind, multicenter phase II study. J Clin Oncol. 2012;30:2046-2054.
80. U.S. National Institutes of Health. ClinicalTrials.gov. https://clinicaltrials.gov/ct2/home. Accessed March 31, 2016.
81. Champiat S, Ileana E, Giaccone G, et al. Incorporating immune-checkpoint inhibitors into systemic therapy of NSCLC. J Thorac Oncol. 2014;9:144-153.
82. Rödel F, Frey B, Gaipl U, et al. Modulation of inflammatory immune reactions by low-dose ionizing radia-tion: molecular mechanisms and clinical application. Curr Med Chem. 2012;19:1741-1750.
83. Djenidi F, Adam J, Goubar A, et al. CD8+CD103+tumor-infiltrating lymphocytes are tumor-specific tissue-resident memory T cells and a prognostic factor for survival in lung cancer patients. J Immunol. 2015;194: 3475-3486.
84. Travis WD. Update on small cell carcinoma and its differentiation from squamous cell carcinoma and other non-small cell carcinomas. Mod Pathol. 2012;25 (suppl 1):S18-S30.
85. Lanphear BP, Buncher CR. Latent period for malignant mesothelioma of occupational origin. J Occup Med. 1992;34:718-721.
86. Robinson BW, Lake RA. Advances in malignant meso-thelioma. N Engl J Med. 2005;353:1591-1603.
87. Peto J, Decarli A, La Vecchia C, et al. The European mesothelioma epidemic. Br J Cancer. 1999;79:666-672.
88. Francisci S, Minicozzi P, Pierannunzio D, et al. Survival patterns in lung and pleural cancer in Europe 1999-2007: results from the EUROCARE-5 study [E-pub ahead of print]. Eur J Cancer. http://dx.doi.org/10.1016/j. ejca.2015.07.033, accessed July 12, 2016.
89. Zalcman G, Mazieres J, Margery J, et al. Bevacizumab for newly diagnosed pleural mesothelioma in the Me-sothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial. Lancet. 2016;387:1405-1414.
90. Shalapour S, Karin M. Immunity, inflammation, and cancer: an eternal fight between good and evil. J Clin Invest. 2015;125:3347-3355.
91. Mossman BT, Shukla A, Heintz NH, et al. New insights into understanding the mechanisms, pathogenesis, and management of malignant mesotheliomas. Am J Pathol. 2013;182:1065-1077.
92. Gandellini P, Andriani F, Merlino G, et al. Complexity in the tumour microenvironment: Cancer associated fibroblast gene expression patterns identify both common and unique features of tumour-stroma crosstalk across cancer types. Semin Cancer Biol. 2015;35:96-106.
93. Kindler HL, Zuo Z, Khattri A, et al. T-cell inflamed phenotype and PDL1 expression in malignant mesothe-lioma [abstract]. J Clin Oncol. 2014;32:5s(suppl):7589.
94. Khattri A, Zuo Z, Husain AN, et al. Immune escape correlates with an inflamed phenotype in malignant mesothelioma [abstract]. J Clin Oncol. 2015;33 (suppl):7566.
95. Ujiie H, Kadota K, Nitadori JI, et al. The tumoral and stromal immune microenvironment in malignant pleural mesothelioma: A comprehensive analysis reveals prognostic immune markers. Oncoimmunology. 2015;4:e1009285.
96. Cedrés S, Ponce-Aix S, Zugazagoitia J, et al. Analysis of expression of programmed cell death 1 ligand 1 (PD-L1) in malignant pleural mesothelioma (MPM). PLoS One. 2015;10:e0121071.
97. Mansfield AS, Roden AC, Peikert T, et al. B7-H1 expression in malignant pleural mesothelioma is associated with sarcomatoid histology and poor prognosis. J Thorac Oncol. 2014;9:1036-1040.
98. Combaz-Lair C, Galateau-Sallé F, McLeer-Florin A, et al. Immune biomarkers PD-1/PD-L1 and TLR3 in malignant pleural mesotheliomas. Hum Pathol. 2016;52:9-18.
99. Calabrò L, Morra A, Fonsatti E, et al. Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single- A rm, phase 2 trial. Lancet Oncol. 2013;14:1104-1111.
100. Calabrò L, Morra A, Fonsatti E, et al. Efficacy and safety of an intensified schedule of tremelimumab for chemotherapy-resistant malignant mesothelioma: an open-label, single- A rm, phase 2 study. Lancet Respir Med. 2015;3:301-309.
101. Byrne MJ, Nowak AK. Modified RECIST criteria for assessment of response in malignant pleural mesothe-lioma. Ann Oncol. 2004;15:257-260.
102. AstraZeneca. AstraZeneca reports top-line result of trem-elimumab monotherapy trial in mesothelioma. https://www.astrazeneca.com/our-company/media-centre/press-releases/2016/astrazeneca-reports-top-line-result-of-tremelimumab-monotherapy-trial-in-mesothelioma-29022 016.html. Accessed July 12, 2016.
103. Alley EW, Molife LR, Santoro A, et al. Clinical safety and efficacy of pembrolizumab (MK-3475) in patients with malignant pleural mesothelioma: Preliminary results from KEYNOTE-028. Cancer Res. 2015;75:CT103.
104. Alley EW, Schellens JHM, Santoro A, et al. Single- A gent pembrolizumab for patients with malignant pleural mesothelioma (MPM). J Thorac Oncol. 2015;10(suppl 2):S195.
105. Hassan R, Thomas A, Patel MR, et al. Safety and clinical activity of avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with advanced, unresectable mesothelioma: a phase Ib trial. Eur J Cancer. 2015;51 (suppl 3):S639.
106. Kindler HL. Immunotherapy for mesothelioma. CTLA4 and PD-1. Minisymposium S17.04 presented at the 16th World Congress on Lung Cancer. September 8, 2015; Denver, CO.
107. Sharabi AB, Lim M, DeWeese TL, et al. Radiation and checkpoint blockade immunotherapy: radio-sensitisation and potential mechanisms of synergy. Lancet Oncol. 2015;16:e498-e509.
108. Eggermont AM, Maio M, Robert C. Immune checkpoint inhibitors in melanoma provide the cornerstones for curative therapies. Semin Oncol. 2015;42:429-435.
109. Serrels A, Lund T, Serrels B, et al. Nuclear FAK controls chemokine transcription, Tregs, and evasion of anti-tumor immunity. Cell. 2015;163:160-173.
110. Topalian SL, Drake CG, Pardoll DM. Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell. 2015;27:450-461.
111. Vonderheide RH. Prospect of targeting the CD40 pathway for cancer therapy. Clin Cancer Res. 2007;13: 1083-1088.
112. Khong A, Cleaver AL, Fahmi Alatas M, et al. The efficacy of tumor debulking surgery is improved by adjuvant immunotherapy using imiquimod and anti-CD40. BMC Cancer. 2014;14:969.
113. Nowak AK, Cook AM, McDonnell AM, et al. A phase 1b clinical trial of the CD40- A ctivating antibody CP-870, 893 in combination with cisplatin and pemetrexed in malignant pleural mesothelioma. Ann Oncol. 2015;26:2483-2490.
114. Weksler B, Lu B. Alterations of the immune system in thymic malignancies. J Thorac Oncol. 2014;9 (suppl 2):S137-S142.
115. Rivoisy C, Besse B, Girard N, et al. Thymic epithelial tumor- A ssociated cytopenia: a 10-year observational study in france. J Thorac Oncol. 2016 Mar;11: 391-399.
116. Weis CA, Yao X, Deng Y, et al. The impact of thymoma histotype on prognosis in a worldwide database. J Thorac Oncol. 2015;10:367-372.
117. Evoli A, Minicuci GM, Vitaliani R, et al. Paraneoplastic diseases associated with thymoma. J Neurol. 2007;254: 756-762.
118. Nakajima J, Okumura M, Yano M, et al. Myasthenia gravis with thymic epithelial tumour: a retrospective analysis of a Japanese database. Eur J Cardiothorac Surg. 2016;49:1510-1515.
119. Anderson G, Jenkinson EJ. Lymphostromal interactions in thymic development and function. Nat Rev Immunol. 2001;1:31-40.
120. Starr TK, Jameson SC, Hogquist KA. Positive and negative selection of T cells. Annu Rev Immunol. 2003;21:139-176.
121. Ströbel P, Chuang WY, Chuvpilo S, et al. Common cellular and diverse genetic basis of thymoma- A ssociated myasthenia gravis: role of MHC class II and AIRE genes and genetic polymorphisms. Ann N Y Acad Sci. 2008;1132:143-156.
122. Ströbel P, Murumägi A, Klein R, et al. Deficiency of the autoimmune regulator AIRE in thymomas is insufficient to elicit autoimmune polyendocrinopathy syndrome type 1 (APS-1). J Pathol. 2007;211:563-571.
123. Scarpino S, Di Napoli A, Stoppacciaro A, et al. Expression of autoimmune regulator gene (AIRE) and T regulatory cells in human thymomas. Clin Exp Immunol. 2007;149:504-512.
124. Nenninger R, Schultz A, Hoffacker V, et al. Abnormal thymocyte development and generation of autoreactive T cells in mixed and cortical thymomas. Lab Invest. 1998;78:743-753.
125. Ströbel P, Hohenberger P, Marx A. Thymoma and thymic carcinoma: molecular pathology and targeted therapy. J Thorac Oncol. 2010;5(suppl 4):S286-S290.
126. Kondo K, Yoshizawa K, Tsuyuguchi M, et al. WHO histo-logic classification is a prognostic indicator in thymoma. Ann Thorac Surg. 2004;77:1183-1188.
127. Marx A, Chan JK, Coindre JM, et al. The 2015 World Health Organization classification of tumors of the thymus: continuity and changes. J Thorac Oncol. 2015;10:1383-1395.
128. Shim HS, Byun CS, Bae MK, et al. Prognostic effect of stromal lymphocyte infiltration in thymic carcinoma. Lung Cancer. 2011;74:338-343.
129. Brown JA, Dorfman DM, Ma FR, et al. Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production. J Immunol. 2003;170:1257-1266.
130. Padda SK, Riess JW, Schwartz EJ, et al. Diffuse high intensity PD-L1 staining in thymic epithelial tumors. J Thorac Oncol. 2015;10:500-508.
131. Katsuya Y, Fujita Y, Horinouchi H, et al. Immunohisto-chemical status of PD-L1 in thymoma and thymic carcinoma. Lung Cancer. 2015;88:154-159.
132. Yokoyama S, Miyoshi H, Nishi T, et al. Clinicopathologic and prognostic implications of Programmed Death Ligand 1 expression in thymoma. Ann Thorac Surg. 2016;101:1361-1369.
133. Takumi Y, Osoegawa A, Hashimoto T, et al. The clini-copathological significance of PD-L1 expression in thymoma. J Thorac Oncol. 2015;10(suppl 2):S510-S511.
134. Naidoo J, Steele K, Sima CS, et al. Defining the immu-nologic phenotype of thymic epithelial tumors [abstract]. J Clin Oncol. 2015;33(suppl):7516.
135. Serpico D, Trama A, Haspinger ER, et al. Available evidence and new biological perspectives on medical treatment of advanced thymic epithelial tumors. Ann Oncol. 2015;26:838-847.
136. Thomas A, Rajan A, Berman A, et al. Sunitinib in patients with chemotherapy-refractory thymoma and thymic carcinoma: an open-label phase 2 trial. Lancet Oncol. 2015;16:177-186.
137. Giaccone G, Thompson J, Crawford J, et al. Phase II study of pembrolizumab in patients with recurrent thymic carcinoma. Presentation O5.5. at the 14th Target Anticancer Therapies Congress. March 21-21, 2016; Washington, DC.
138. Michot JM, Bigenwald C, Champiat S, et al. Immune-related adverse events with immune checkpoint blockade: a comprehensive review. Eur J Cancer. 2016;54:139-148.